ZYUS Life Sciences Corp., a Canadian-based life sciences company, appointed Scott Livingstone vice president of clinical research with its wholly owned subsidiary, ZYUS Life Sciences Inc.

Livingstone will lead the company’s clinical research initiatives and oversee ZYUS’ Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

Prior to joining ZYUS, Livingstone served as the CEO of the Saskatchewan Health Information Network, President and CEO of the Saskatchewan Cancer Agency, chair of both the National Steering Committee and the Saskatchewan Provincial Advisory Committee for the Pan Canadian Oncology Drug Review, and the inaugural President and CEO of the Saskatchewan Health Authority.

“We are pleased to announce Scott Livingstone’s appointment to vice president of clinical research with ZYUS Life Sciences Inc.,” said Brent Zettl, President, and CEO of the company. “His leadership and experience will be instrumental in guiding our clinical research initiatives, particularly in overseeing the Phase 2 Clinical Trial for Trichomylin softgel capsules. This strategic addition to our team reaffirms ZYUS’ commitment to the development of evidence-based solutions to address unmet patient needs.”

“I’m honored to lead ZYUS’ clinical research initiatives, driven by a profound dedication to improving lives through innovative discoveries,” said Livingstone. “With a dedicated team and a relentless pursuit of scientific innovation, we aim to uncover transformative cannabinoid-based therapies that benefit patients globally.”